Skip to main navigation
Home Story Platform Pipeline People Publications Careers Investors & Press Contact
Home
/
Investor Relations
/
Press Releases
Overview Press Releases Events & Presentations Financials & SEC Filings Stock Information Analyst Coverage Corporate Governance Investor FAQs Email Alerts
Investor Contacts
ir@allovir.com
Media Contacts
AlloVirPR@scientpr.com

Press Releases

Press Releases

Feb 23, 2023
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
PDF Version
Feb 15, 2023
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
PDF Version
Feb 15, 2023
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
PDF Version
Feb 01, 2023
AlloVir to Participate in the SVB Securities Global Biopharma Conference
PDF Version
Jan 09, 2023
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 11 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet
Allovir Logo

Waltham

1100 Winter Street
Waltham, MA 02451

Houston

2925 Richmond Ave
Suite 1200
Houston, TX 77098
 

Company

About Us Contact Us 617-433-2605
Contact Careers
AlloVir, Inc. ©2023 All rights reserved

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yes no

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yes no